丰山集团：钠离子电解液销售额占公司合并报表营业收入比例较小

Core Viewpoint - The company clarifies that its main business remains focused on the production, research, and sales of raw medicines and formulations, despite media reports linking it to the "solid-state battery" concept [1] Business Operations - The company's main business has not changed, and its subsidiary, Fengshan Quannuo, primarily sells lithium-ion electrolytes, with sodium-ion electrolytes making up a relatively small portion of sales [1] - As of the first half of 2025, sodium-ion electrolyte sales are expected to account for only 0.01% of the company's consolidated revenue [1] Research and Development - The important research results published by Professor Zhang Qiang's team from Tsinghua University are not related to the company's commissioned research and development project [1] - The collaboration with Tsinghua University is currently in the preliminary research and development phase, with a small contract amount, and the technology development project is scheduled to last until December 31, 2028 [1] - There is significant uncertainty regarding the subsequent research outcomes and their commercialization [1]